Form 4: Kura Oncology Director Carol Schafer Acquires Options in Recent Transaction
SEC Form 4
Director Carol Schafer acquired options to purchase 26,000 shares of Kura Oncology stock on June 5, 2024.
Summary
- Carol Schafer, a director of Kura Oncology, Inc., reported a transaction involving derivative securities.
- On June 5, 2024, Schafer acquired an option to purchase 26,000 shares of Kura Oncology's common stock at an exercise price of $21.79.
- The option vests in full on the one-year anniversary of the grant date and expires on June 4, 2034.
- Following the reported transaction, Schafer beneficially owns 26,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral report of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to the market regarding their investment activities.
Stakeholder Impact
- The transaction provides shareholders with insight into the investment activities of a company director.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of the transaction where Carol Schafer acquired options to purchase common stock. |
| 06/04/2034 | Expiration date of the option to purchase common stock. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.